The combined company, Clywedog Therapeutics, will bring a portfolio that includes three differentiated, clinical stage product candidates which are being…
SEATTLE, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Umoja Biopharma, the clinical-stage leader of in vivo cell therapies that aim to…
-- AjD Represents an Area of Significant Unmet Need; No U.S. Food and Drug Administration (FDA)-Approved Therapies Available -- --…
BEDFORD, Mass., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (Nasdaq: OCUL) (“Ocular”, the “Company”), an integrated biopharmaceutical company…
Based on previously reported positive Phase 1 results, Kynexis is advancing KYN-5356, a first-in-class KAT-II inhibitor, into a Phase 2…
Pediatric participants demonstrated large gains in cone-mediated vision; therapy remains well tolerated with no ocular serious adverse events or dose-limiting…
WAYNE, Pa., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing…
RESEARCH TRIANGLE PARK, N.C., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Merakris Therapeutics, a regenerative medicine company developing biologic drug therapies…
CAMPBELL, Calif., Sept. 29, 2025 /PRNewswire/ -- Saama, an established leader in AI-driven solutions and services within Health Sciences, is introducing…
Grant supports CHOP's dedication to understanding and treating rare tumors PHILADELPHIA, Sept. 29, 2025 /PRNewswire/ -- Children's Hospital of Philadelphia…